PubMed

Is the current regulatory framework for direct-to-consumer microbiome-based tests sufficient to protect consumers from medical, economic, and dignitary harms?

PMID: 41450770 · 2025-12-24

D, i, a, n, e, , E, , H, o, f, f, m, a, n, n, ;, , F, e, l, i, c, i, a, , D, , L, a, n, g, e, l, ;, , E, r, i, k, , C, , v, o, n, , R, o, s, e, n, v, i, n, g, e, ;, , F, r, a, n, c, i, s, , B, , P, a, l, u, m, b, o, ;, , M, a, r, y, -, C, l, a, i, r, e, , R, o, g, h, m, a, n, n, ;, , J, a, c, q, u, e, s, , R, a, v, e, l

ЖурналJournal of law and the biosciences

Год2025-12-24

PMID41450770

Аннотация

This article offers a thorough analysis of an important public health issue-the lack of regulation of companies selling direct-to-consumer (DTC) microbiome-based tests. These companies invite curious consumers and desperate patients to submit stool and/or vaginal secretion samples to them for analysis. Purchasers receive a report about the composition of their gut and/or vaginal microbiomes with recommendations to change their diet or take certain dietary supplements. The piece is grounded in a

Официальный источник

Открыть в PubMed →

Данные получены из PubMed / NCBI. Полный текст и наиболее актуальную информацию всегда смотрите в официальной записи.